Currently browsing tag

johnson

J&J profit beats forecasts, helped by lower taxes, cost cuts

Shares of the diversified healthcare company rose almost 5 percent to $101.18 as investors shrugged off fourth-quarter sales and a 2016 revenue outlook that were both below analysts' estimates. Edward Jones analyst Ashtyn Evans said investors were cheered by J&J's vow to make more of its medical devices market leaders and to launch 30 new devices this year, including a new insulin pump. Device sales fell 3.3 percent to $6.43 billion in the fourth quarter.

J&J, Bavarian Nordic start clinical tests in Ebola vaccine race

By Ben Hirschler LONDON (Reuters) – Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark’s Bavarian Nordic, making it the third such shot to enter human testing. The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year. Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. …